Medical Patent Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Regenerative Medicine
BioTime Licenses Human Embryonic Stem Cell Technology from the Wisconsin Alumni Research Foundation
January 25th, 2008
BioTime, Inc. (OTCBB:BTIM) announced it has signed a licensing agreement with the Wisconsin Alumni Research Foundation (WARF) to 173 patents and patent applications filed internationally relating to human embryonic stem cell technology created by James Thomson at the University of Wisconsin-Madison. BioTime develops blood plasma volume expanders and has recently entered the field of regenerative medicine through its wholly owned subsidiary, Embryome Sciences, Inc., through which it plans to develop new medical and research products using embryonic stem cell technology. Embryome Sciences plans to develop and commercialize a technology platform called...
Source: Medical Patent Business Week (2008-01-25)
|
